Browsing Greinar- HÍ by Author "Aaltonen, Kalle"

Now showing items 1-2 of 2

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

Chatzidionysiou, Katerina; Delcoigne, Bénédicte; Frisell, Thomas; Hetland, Merete L; Glintborg, Bente; dreyer, lene; Cordtz, René; Zobbe, Kristian; Nordström, Dan; Trokovic, Nina; Aaltonen, Kalle; Provan, Sella Aarrestad; Gröndal, Gerður; Gudbjornsson, Bjorn; Askling, Johan (BMJ, 2020-09-08)

[No abstract available]
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis

Lindström, Ulf; Glintborg, Bente; Di Giuseppe, Daniela; Nordström, Dan; Aarrestad Provan, Sella; Gudbjornsson, Bjorn; Askling, Johan; Hetland, Merete Lund; Aaltonen, Kalle; Krogh, Niels Steen; Geirsson, Árni J.; Jacobsson, Lennart (BMJ, 2019-10)

Objective Although clinical trials support equivalence of originator products and biosimilars for etanercept and infliximab, real-world studies among biologics-naïve patients with spondyloarthritis (SpA) are lacking. The objectives were to compare ...

Now showing items 1-2 of 2

Search Opin vísindi